Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Sunday, November 1, 2026

Back to today

From X

@StableBread

Fajasy on X

When I first wrote up Quantum $QMCO on May 6, 2026, at $7.36/share, it traded at ~0.85x EV/Sales. By my August 16 update, where I said I’d look again if its sales multiple gave back part of its re-rate while demand still outran supply, $QMCO was at $26.11. The stock then ran another 32.1% to a $34.50 close on October 2, 2026, a week before $QMCO fired its CFO. At $20.25/share, $QMCO has a market cap of $798.1M and an EV of $825.3M ($902.3M on 44.6M diluted shares - $77.0M of cash, including the $22.6M warrant and option holders would pay to exercise, with no debt). That’s 2.8x TTM revenue, down from 4.9x at the October 2 peak and 3.7x at the $26.11 price in my August update (measured the same way), but still 34.4x the September quarter’s $6M ±$1M of adjusted EBITDA guidance, annualized. So $QMCO isn’t cheap on profits yet, since its adjusted EBITDA margin is still under 10%. The sales multiple has given back part of its re-rate, and by management’s account, demand still outran supply as of the June-quarter call.
@ACapitalLP 1 click

A Capital on X

𝙀𝙭-𝘼𝙣𝙩𝙚 𝙫𝙨. 𝙀𝙭-𝙋𝙤𝙨𝙩 𝘾𝙖𝙩𝙖𝙡𝙮𝙨𝙩𝙨 One of the more important distinctions in catalyst-driven investing is “ex-ante” vs. “ex-post” catalysts (my words). Both can offer significant valuation dislocations, but the mechanics of realizing that value are fundamentally different… “Ex-ante” trades are cleaner. You identify a gap between price and intrinsic value, with an upcoming event (spin-off, asset sale, regulatory decision, etc.) that can force the market to reassess the security. You have a mechanism for value realization and at least (some) visibility into timing. “Ex-post” trades are much harder. Something unexpected happens, investors “shoot first, ask questions later,” and the stock collapses. Deep-value and distressed investors love these situations because the apparent discount to intrinsic value can be enormous. But the event that created the dislocation does absolutely nothing to resolve it. Look at $BAYN, where an identifiable June litigation catalyst helped drive a meaningful rerating. Contrast that with $CODI following its Lugano accounting scandal, where the stock collapsed from the high teens into the single digits. It took months of financial reporting progress, improved visibility, and renewed confidence for the stock to recover even partially. On the flip side, look at $VRRM following its major contract loss, where what initially looked like a massive overreaction was followed by further deterioration, with the stock now at $2.80. The irony is that ex-post trades almost always require a new “mini ex-ante” catalyst to unlock value. Otherwise you’re simply betting that the market eventually recognizes something is cheap. That can take years, and even then the security may never recover anywhere close to its prior valuation. The lesson is that a catalyst creating a valuation gap is not the same as a catalyst closing it. Cheapness is not a catalyst, and the magnitude of a selloff tells you very little about the probability of recovery…

Investor Letters

All letters

When the liquidity does not add up

Arbor Realty Trust’s dividend suspension is presented as creating $60 million of liquidity, raising questions about its ability to meet…

ABR $2.2B
John Hempton's Newsletter 3 clicks

Verra veerer

Verra Mobility’s Avis termination threatens 2027 earnings, while Government Solutions profit rose 25% and implied fourth-quarter guidance…

VRRM $505M
The Oak Bloke 2 clicks

FTAI 3Q26: Aero margins in focus

FTAI’s Aerospace Products margin rebounded to 31% as CFM56 module output rose, while Power deposits and contracted deliveries fund its 2027…

FTAI $16B
Stock Thoughts 4 clicks

Microsoft's AI Boom Has A Cost

Microsoft’s Azure grew 48% as AI monetization accelerated, but doubled CapEx, largely for CPUs and GPUs, reduced quarterly free cash flow…

MSFT $3.9T
Yiannis Zourmpanos 1 click
T · short

At&t INC

AT&T’s stalled deleveraging and share repurchase case has prompted a bearish turn on the telecom stock.

T $144B
Value Investors Club

CVX Earnings Review

Chevron’s Q3 revenue rose 35% to $65.2 billion and EBITDA 75% to $20.2 billion, while production trailed guidance and refining margins…

CVX $465B
Cestrian Capital Research 3 clicks

SNY Earnings Review

Sanofi raised FY26 guidance after Q3 sales grew 14.3% at constant currency, led by 34.8% Dupixent growth; vaccines declined 6.6%.

SNY $108B
Cestrian Capital Research 1 click

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 67 of 266

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.